Therefore, KDM5B is a recently identified therapeutic target in B-ALL, the impaired repression of which could be restored by the targeted inhibition of casein kinase 2 (CK2) [56]. This evidence concerns the gene KDM5B and precursor B-cell acute lymphoblastic leukemia.